Patent · US Active

Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles

US9970938B2 · kind B2 · utility

1Cited by

1References

60Claims

0Family size

Assignee

Basilea Pharmaceutica AG · CH

Inventors

Heidi Lane · Biel-Benken, CH
Felix Bachmann · Basel, CH
Madlaina Breuleux · Basel, CH
Michael Boutros · Heidelberg, DE
Daniel Gilbert · Koblenzer Straße, DE
Xian Zhang · Beijing, CN

Key dates

Filing date	Mar 4, 2016
Grant date	May 15, 2018
Priority date	—
Expiry date	Mar 4, 2036

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Use of BUBR1 as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject, wherein the compound is a compound of general formula Iwherein

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.